ELAVL1 Human shRNA Plasmid Kit (Locus ID 1994)
SKU
TR313235
ELAVL1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
$883.00
In Stock*
Specifications
| Product Data | |
| Locus ID | 1994 |
|---|---|
| Synonyms | ELAV1; Hua; HUR; MelG |
| Vector | pRS |
| E. coli Selection | Ampicillin |
| Mammalian Cell Selection | Puromycin |
| Format | Retroviral plasmids |
| Components | ELAVL1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 1994). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq | NM_001419, NM_001419.1, NM_001419.2, BC003376, BC003376.2, BM664469, BM696191, NM_001419.3 |
| UniProt ID | Q15717 |
| Summary | The protein encoded by this gene is a member of the ELAVL family of RNA-binding proteins that contain several RNA recognition motifs, and selectively bind AU-rich elements (AREs) found in the 3' untranslated regions of mRNAs. AREs signal degradation of mRNAs as a means to regulate gene expression, thus by binding AREs, the ELAVL family of proteins play a role in stabilizing ARE-containing mRNAs. This gene has been implicated in a variety of biological processes and has been linked to a number of diseases, including cancer. It is highly expressed in many cancers, and could be potentially useful in cancer diagnosis, prognosis, and therapy. provided by RefSeq, Sep 2012 |
| shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
| Storage | Store at -20°C |
| Shipping | Ambient |
Reviews
Documents
Resources
Citations
The alternative spliced 3'-UTR mediated differential secretion of macrophage colony stimulating factor in breast cancer cells
Woo, Chambers
Biochem. Biophys. Res. Commun. (2020) 525 (4), 1004-1010 DOI: 10.1016/j.bbrc.2020.03.007
Woo, Chambers
Biochem. Biophys. Res. Commun. (2020) 525 (4), 1004-1010 DOI: 10.1016/j.bbrc.2020.03.007
Cited by 1
AI Summary: OriGene's HuR shRNA (TI352933) was used to silence HuR expression in BT20 breast cancer cells, enabling the study of HuR's role in regulating CSF-1 protein secretion mediated by alternative splicing of CSF-1 mRNA 3'UTRs.
Snippet: was used. 2.5. HuR overexpression and silencing in BT20 cells. HuR-pcDNA3.1 was transfected for overexpression. For silencing, HuR shRNA (Origene, TI352933) was transfected. 2.6. CSF-1 sandwich ELISA. Secreted CSF
HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects
Hubers, Valderrama-Carvajal, Laframboise et al
Hum. Mol. Genet. (2011) 20 (3), 553-79 DOI: 10.1093/hmg/ddq500
Hubers, Valderrama-Carvajal, Laframboise et al
Hum. Mol. Genet. (2011) 20 (3), 553-79 DOI: 10.1093/hmg/ddq500
Cited by 139
AI Summary: In this study, OriGene’s HuD Myc-DDK-tagged cDNA (Cat# RC208307) and SMN Myc-DDK-tagged cDNA (Cat# RC200236) expression plasmids were used to investigate protein interactions and overexpression effects, enabling the authors to demonstrate the role of HuD in rescuing SMA-like neuronal defects.
Snippet: Skip Navigation.
Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer
Woo, Yi, Lamb et al
Mol Cell Biol (2011) 31 (1), 215-25 DOI: 10.1128/MCB.01031-10
Woo, Yi, Lamb et al
Mol Cell Biol (2011) 31 (1), 215-25 DOI: 10.1128/MCB.01031-10
AI Summary: OriGene products contributed to this study by providing the c-fms expression plasmid (RC200176) and HuR expression plasmid (RC200446), which were used to investigate the regulatory effects of vigilin and HuR on c-fms mRNA and protein expression in breast cancer cells.
Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer
Woo, Yi, Lamb et al
Mol. Cell. Biol. (2011) 31 (1), 215-25 DOI: 10.1128/MCB.01031-10
Woo, Yi, Lamb et al
Mol. Cell. Biol. (2011) 31 (1), 215-25 DOI: 10.1128/MCB.01031-10
Cited by 11
AI Summary: In this study, the OriGene shRNA negative control (TR30003) targeting a non-effective 29-nt GFP sequence was used as a control to validate the specificity of vigilin and HuR knockdown experiments investigating their roles in regulating c-fms expression in breast cancer.
Snippet: An shRNA containing a noneffective 29-nt GFP sequence (TR30003, Origene) was used as a negative control [(−) CTRL]. ... We knocked down vigilin or HuR and used immunoprecipitation followed by qRT-PCR to determine the level of endogenous c-fms or luciferase mRNA (in
Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer
Woo, Zhou, Yi et al
Oncogene (2009) 28 (9), 1176-86 DOI: 10.1038/onc.2008.469
Woo, Zhou, Yi et al
Oncogene (2009) 28 (9), 1176-86 DOI: 10.1038/onc.2008.469
Cited by 35
AI Summary: OriGene products contributed to this study by providing the c-fms (CSF1R) cDNA clone (OriGene, SC119706), which was used for gene expression and functional analyses to investigate the regulation of c-fms by HuR in breast cancer.
Showing 1-5 of 5 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
